Remarkably, we must emphasize the importance of an adequate selection of patients for a future clinical trial involving these target drugs, since only 26% of the cervical cancer patients included in TCGA (Firehose Legacy study) showed upregulation of, at least, one of the genes of these signaling pathways (EGFR, PTAFR, LPCAT1, LPCAT2, LPCAT3, LPCAT4, and PLA2G4A). The gene discussed is LPCAT4; the disease is cervical carcinoma.